In clinical settings, TLR2 inhibitors are being investigated in combination regimens, enhancing the efficacy of chemotherapy, anti-angiogenic agents (e.g., bevacizumab), and immunotherapies, showing synergy with TLR9 agonists (CpG ODN) in melanoma models [29]. Here, TLR9 is linked to melanoma.